{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-006909","form_type":"8-K","ticker":"STIM","cik":"0001227636","company_name":"Neuronetics, Inc.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.607235+00:00","generated_at":"2026-06-02T16:28:05.855352+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Neuronetics Q1 revenue $17.4M (+12% YoY); FDA clearance for adolescent MDD expands TAM by ~35%","bullets":["Revenue $17.4M (+12% YoY); U.S. treatment session revenue $13.0M (+22% YoY) driven by higher utilization.","Net loss $(7.9)M ($0.27/share) improved from $(10.5)M ($0.38/share) in Q1 2023; EBITDA $(6.3)M vs $(9.4)M.","NeuroStar received FDA clearance as first-line adjunct TMS for adolescents (15-21) with MDD; total addressable market increased ~35%.","Shipped 41 systems (vs 49 in Q1 2023); system revenue down 14% due to customer credit challenges and Change Health cyberattack.","Q2 2024 revenue guidance $18-19M; FY2024 revenue $78-80M; operating expenses $80-84M."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-006909","json":"https://secwatch.observer/filing/0001558370-24-006909.json","markdown":"https://secwatch.observer/filing/0001558370-24-006909.md","text":"https://secwatch.observer/filing/0001558370-24-006909.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1227636/000155837024006909/0001558370-24-006909-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1227636/000155837024006909/stim-20240507x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T16:28:05.855352+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"edcd745a650ee0478baf6f7107b36af46e42d9fb","claim":"Neuronetics, Inc. reported first quarter of 2024; three months ended March 31, 2024 results: revenue $17.4 million, net income $(7.9) million, or $(0.27) per share, EPS $(0.27) per share.","evidence_excerpt":"therapies in the world, today announced its financial and operating results for the first quarter of 2024. First Quarter 2024 Highlights ● First quarter 2024 revenue of $17.4 million, a 12% increase as compared to the first quarter 2023 ● U.S. treatment session revenue increased by 22% versus the first quarter of 2023 ● U.S. NeuroStar Advanced Therapy system","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1227636/000155837024006909/0001558370-24-006909-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2024; three months ended March 31, 2024"},{"label":"Revenue","value":"$17.4 million"},{"label":"Net income","value":"$(7.9) million, or $(0.27) per share"},{"label":"EPS","value":"$(0.27) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}